(redirected from Adrenomyeloneuropathy)
Also found in: Dictionary, Medical, Wikipedia.
Related to Adrenomyeloneuropathy: adrenoleukodystrophy
Category filter:
AMNAirman (USAF rank)
AMNAdrenomyeloneuropathy (form of neurological disease ALD)
AMNAgile Media Network (Japan)
AMNAudioman Nodes
AMNAfghan Mission Network (information system)
AMNAdvanced Media Network
AMNAboriginal Mapping Network (est. 1998; Canada)
AMNArt Museum Network
AMNAmerican Medical News
AMNAbstract Machine Notation (formal methods)
AMNArtificial Mains Network
AMNAny Minute Now
AMNAmicale Motocycliste de Nice (French: Friendly Riders of Nice; motorcycle club; Nice, France)
AMNAmerican Mobile Nurses
AMNActa Musei Napocensis
AMNAutonomous Maritime Navigation
AMNAnnuity Market News
AMNAnsaldo Meccanico Nucleare
AMNAir Management Node (BFTT/CSTS system on LHD class ships)
AMNAlkali Metal Nitrite
AMNAccess Media Network, Inc.
AMNAmerican Motorcycle Network
AMN(USN Rating) Aviation Structural Mechanic (Hydraulics)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
This case report describes an adult onset of adrenomyeloneuropathy (AMN) due to a single gene mutation.
Nutra Pharma is a biotechnology company that is developing treatments for adrenomyeloneuropathy, HIV and multiple sclerosis.
X-linked inheritance strongly suggests adrenomyeloneuropathy, Fabry disease, pre-mutation X-fragile diagnosis; dominant inheritance suggests cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL), collagen type IV (Col IV) mutation, Nasu-Hakola disease (NHD), adult-onset autosomal dominant leucodystrophies (ADLD) and Alexander disease diagnosis.
There are seven subtypes of ALD, ranging from the rapidly progressive childhood cerebral form to the more slowly progressive adrenomyeloneuropathy (AMN) in adults.
Nutra Pharma Corp., a biotechnology company developing drugs for HIV and Multiple Sclerosis, today announced that ReceptoPharm has received Ethics Committee approval in the UK to begin its Phase IIb human clinical trial for the treatment of Adrenomyeloneuropathy (AMN).
Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci U S A 1988;85:7647-51.